ArticleMethods in molecular biology (Clifton, N.J.)2026
Enhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic engineering techniques.
Indexed as
Identifiers
42108345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.